• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    6/4/24 12:31:07 PM ET
    $ANNX
    $CCM
    $EQ
    $FRES
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ANNX alert in real time by email

    Gainers

    • Concord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million.
    • Annexon (NASDAQ:ANNX) shares increased by 32.96% to $6.09. The company's market cap stands at $562.7 million.
    • Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 26.7% to $14.9. The company's market cap stands at $833.4 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 22.59% to $7.0. The market value of their outstanding shares is at $7.3 million.
    • Fresh2 Group (NASDAQ:FRES) stock moved upwards by 21.12% to $0.43. The company's market cap stands at $10.5 million.
    • I-MAB (NASDAQ:IMAB) stock rose 20.88% to $1.91. The company's market cap stands at $154.4 million.

    Losers

    • ENDRA Life Sciences (NASDAQ:NDRA) shares decreased by 64.4% to $0.08 during Tuesday's regular session.
    • Equillium (NASDAQ:EQ) stock fell 22.45% to $1.14. The market value of their outstanding shares is at $40.1 million.
    • Microbot Medical (NASDAQ:MBOT) shares declined by 18.85% to $1.12. The market value of their outstanding shares is at $16.1 million.
    • Inspire Veterinary (NASDAQ:IVP) stock decreased by 18.36% to $2.58. The market value of their outstanding shares is at $2.5 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares fell 18.3% to $0.22. The market value of their outstanding shares is at $12.2 million.
    • NewGenIvf Group (NASDAQ:NIVF) stock fell 17.4% to $1.14. The company's market cap stands at $11.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX
    $CCM
    $EQ
    $FRES

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    3/19/2026Buy
    Jefferies
    Equillium Inc.
    $EQ
    3/13/2026$12.00Buy
    Roth Capital
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    More analyst ratings

    $ANNX
    $CCM
    $EQ
    $FRES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yang Jianyu

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:33 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:12 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Olema Pharmaceuticals

    Jefferies resumed coverage of Olema Pharmaceuticals with a rating of Buy

    3/19/26 8:27:01 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Equillium with a new price target

    Roth Capital initiated coverage of Equillium with a rating of Buy and set a new price target of $12.00

    3/13/26 8:47:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    SEC Filings

    View All

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    3/17/26 9:27:19 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/16/26 4:03:51 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/16/26 12:43:51 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Equillium to Participate in the 38th Annual Roth Conference

    LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a potent

    3/18/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

    SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California. Poster Presentation Details Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alphaPoster/Abstract: 2950Session: Experimental and Molecular Therapeutics: Cellular

    3/17/26 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Microbot Medical® to Participate at the 38th Annual Roth Conference

    HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23rd. Mr. Gadot will highlight the Company's recent achievements, and how LIBERTY is

    3/17/26 8:40:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    Leadership Updates

    Live Leadership Updates

    View All

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $CCM
    $EQ
    $FRES
    Financials

    Live finance-specific insights

    View All

    Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potential to Be the First Approved Vision Sparing Therapy for the Treatment of Eight Million GA Patients Worldwide ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept Study Ongoing with Expected 2026

    11/10/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2025

    BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network

    9/26/25 7:30:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

    3/31/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care